Prospective risk of melanoma has decreased substantially in both mutation-positive and mutation-negative families over 4 decades, while melanoma has greatly increased in the general population, a recent study found. Researchers assessed risks of melanoma and other cancers in 1,226 members of 56 families followed for up to 4 decades to population rates in the Surveillance, Epidemiology, and End Results (SEER) program. All families were tested for mutations in CDKN2A and CDK4; 29 were mutation-positive and 27 mutation-negative. They compared rates of invasive melanomas, both first and second, by family mutation status, to SEER. Findings included:
- Comparing 3 calendar periods of the study, risk of first primary melanoma decreased slightly.
- Risks of melanoma after first examination, however, were approximately one-third the risks prior to the first examination, in both mutation-positive and mutation-negative families.
- Among patients with melanoma, risk of a second melanoma was increased 10-fold in all families; risk was somewhat higher in mutation-positive families.
- Risks of other second cancers were increased only for pancreatic cancer after melanoma in mutation-positive families.
Tucker MA, Elder DE, Curry M, et al. Risks of melanoma and other cancers in melanoma-prone families over four decades. [Published online ahead of print February 2, 2018]. J Invest Dermatol. doi:10.1016/j.jid.2018.01.021.
This Week's Must Reads
Latent TB Prevalent in Patients with Psoriasis, J Dermatolog Treat; 2018 Nov; Lee, Amin, et al
Understanding Scope of Cutaneous Pain in Psoriasis, J Dermatolog Treat; ePub 2018 Sep 26; Pithadia, et al
Ixekizumab Proves Effective in Psoriasis Treatment, J Clin Pharmacol; 2018 Nov; Chigutsa, et al
QOL Impaired in Young Adults with Psoriasis, J Dermatolog Treat; ePub 2018 Sep 7; Bronckers, et al
Vascular Inflammation, CAD Indices, and Psoriasis, JAMA Cardiology; ePub 2018 Sep 12; Joshi, et al
Must Reads in Melanoma
Follicular Involvement Frequent in Lentigo Maligna, J Am Acad Dermatol; ePub 2018 Sep 26; Connolly, et al
Sentinel Lymph Node Positivity Markers in Melanoma, J Am Acad Dermatol; ePub 2018 Sep 18; Conic, et al
Nevus Development Trajectory from Age 3 to 16 Years, JAMA Dermatology; ePub 2018 Sep 12; Asdigian, et al
Mohs Surgery Effective for Invasive Melanomas, Dermatolog Surg; ePub 2018 Sep 7; Degesys, et al
Age, Sentinel Lymph Node Risk Link in Melanoma, J Am Acad Dermatol; ePub 2018 Aug 27; Hanna, et al